Introduction
============

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most devastating malignancies with a 5-year survival rate less than 5% [@B1]. Early diagnosis in combination with comprehensive therapies including surgical resection, adjuvant chemotherapy and radiotherapy can increase the 5-year survival rate significantly [@B2]. The clinical symptoms of PDAC are usually insidious due to the concealed location. When the PDAC tumor is large enough to affect the adjacent organs or nerves, it is often too advanced to be treated radically. Currently, carbohydrate antigen 19-9 (CA 19-9) is widely acknowledged as a marker of PDAC diagnosis [@B3], but it is not an ideal tumor biomarker for early diagnosis of PDAC due to its low sensitivity [@B4]. Thus, it is necessary to search novel biomarkers for early diagnosis of PDAC for the sake of reducing the high morbidity and mortality of PDAC.

Long non-coding RNA (lncRNA) generally refers to any non-coding RNA with a length of more than 200bp and without protein coding potential [@B5]. Although IncRNA was suggested as "junk" in the human genome, increasing evidence has revealed that lncRNA has multiple biological functions in gene expression including epigenetic regulation, transcriptional interference and post-transcriptional regulation [@B6]-[@B8]. Over the past few years, comprehensive studies have demonstrated that lncRNA is closely related to the progression of a variety of diseases including autoimmune diseases, cardiovascular diseases and cancers [@B9]-[@B12]. Notably, previous studies showed that some lncRNAs aberrantly expressed in the process of tumorigenesis and cancer progression, suggesting that they may be potential biomarkers for the diagnosis and prognostic prediction of cancer patients [@B13]. Zhou *et al.* [@B14] reported that the expression level of H19 in the plasma of gastric cancer patients was significantly higher than that in healthy controls. Li and colleagues reported that lncRNA ZFAS1 functioned as an oncogene in hepatocellular carcinoma (HCC) and was associated with poor prognosis and metastasis [@B15]. Several lncRNAs (AFAP1-AS1, ENST00000480739 and BC008363) also showed a potential diagnostic or prognostic value in patients with PDAC [@B16]-[@B18]. However, the role of lncRNA involvement in carcinogenesis and cancer progression remains unknown entirely.

In the present study, we analyzed and compared lncRNA and mRNA expression profiles between PDAC tissues and paired adjacent noncancerous tissues by microarray, and consequently validated them by RT-qPCR, hoping that the obtained results would provide further insights into the pathogenesis of PDAC.

Materials and Methods
=====================

Patients and tissue collection
------------------------------

Included in this study were 71 cancer tissues and 71 adjacent normal tissues obtained from PDAC patients who underwent radical or partial resection of the pancreas at Changhai Hospital (Shanghai, China) between April 2014 and March 2016. No patient had received chemotherapy or radiotherapy before sample collection. The corresponding adjacent non-cancerous tissues were taken at least 5cm away from the tumor edge. All the specimens were stored with RNAlater^®^ Solution (life technologies, Carlsbad, CA) at 4°C overnight, and then transferred to -80°C for long-term storage after removing the supernatant. The diagnosis of PDAC in all patients was confirmed by histopathology by two experienced pathologists (Hui Jiang and Jianming Zheng). Clinicopathological data were obtained from the Department of Pathology, Changhai Hospital. Amongst these specimens, 10 (5 pairs) were used for lncRNA microarray analysis, and 66 pairs were analyzed to validate the microarray results by RT-qPCR.

RNA extraction and reverse transcription
----------------------------------------

Total RNA was extracted from the frozen PDAC tissues and corresponding adjacent normal tissues by RNAiso Plus (TAKARA, Dalian, China). Each specimen was quantified with the NanoDrop Lite spectrophotometer (Thermo Scientific, MA) and RNA integrity was assessed by standard denaturing agarose gel electrophoresis. Total-RNA (1000ng) was converted to cDNA by reverse-transcription with ReverTra Ace qPCR RT Kit (TOYOBO, Osaka, Japan). The reverse transcription procedure was performed at 65℃ for 5 min, 42℃ for 18 min, and 98℃ for 5min.

Microarray analysis
-------------------

In total, 10 specimens (5 pairs) obtained from PDAC patients were included in human microarray analysis by using the Agilent Array platform (Agilent Technology) according to the manufacturer\'s standard protocols. After removal of rRNA, mRNA was purified from total RNA with mRNA-ONLY™ Eukaryotic mRNA Isolation Kit (Epicentre, WI). Then, each specimen was amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3\' bias by a random priming method. The labeled cRNAs were hybridized onto the Human LncRNA Array v2.0 (8 x 60K, Arraystar). The slices were washed and the arrays were scanned with Agilent Scanner (G2505B). The acquired array images were analyzed by using Agilent Feature Extraction software (version 10.7.3.1). Quantile normalization and subsequent data processing were performed using the GeneSpring GX v11.5.1 software package (Agilent Technologies). Differentially expressed LncRNAs and mRNAs with statistical significance between the two groups were identified through Volcano Plot filtering. Differentially expressed LncRNAs and mRNAs between two paired specimens were identified through Fold Change filtering.

Gene Ontology (GO) enrichment and KEGG pathway analysis
-------------------------------------------------------

GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. The GO categories are derived from Gene Ontology ([www.geneontology.org](http://www.geneontology.org)), which comprise three structured networks of defined terms that describe gene product attributes. The P-value denotes the significance of GO Term enrichment in the differentially expressed mRNA list. Besides, Base on the latest Kyoto Encyclopedia of Genes and Genomes (KEGG) database, we provided pathway analysis for differentially expressed mRNAs, knowing that this analysis allows users to determine whether the biological pathway has a significant enrichment of differentially expressed mRNAs. The P-value denotes the significance of the Pathway. The less the P-value is, the more significant the GO Term and the Pathway are (The P-value cut-off is 0.05).

Real-time polymerase chain reaction (PCR)
-----------------------------------------

Subsequently, cDNA was subjected to a polymerase chain reaction (PCR) amplification step in triplicate using the Step One Plus™ System (Life Technologies, Waltham, MA). Real-time PCR was conducted by using SYBR Premix Ex Taq (TliRNaseH Plus) (TAKARA, Dalian, China) with ROX Reference Dye. All the ΔCt values of the specimens were normalized to the endogenous control U6 level. The details of primers used in PCR are shown in Table [1](#T1){ref-type="table"}. The PCR amplification cycle was applied as follows: one cycle at 95℃ for min; 40 cycles of 95℃ for 5s, and 60℃ for 30 s.

Statistical analysis
--------------------

All the statistical analyses were conducted by SPSS 19.0 (SPSS, INC; Chicago, IL). Independent-samples t-test was used in differential expression levels of lncRNAs and mRNAs. GO and KEGG pathway analyses were evaluated by Fisher\'s exact test. χ^2^-test was used to estimate the differences between groups. Kaplan-Meier analysis (KM analysis), univariate and multivariate Cox regression were applied to evaluate the outcomes of patients with PDAC. Two-tailed *P* value was employed and *P*\<0.05 was considered statistically significant.

Results
=======

Microarray expression profiles
------------------------------

Arraystar (Rockville, MD) Human LncRNA Microarray v2.0 is designed for global profiling of human LncRNAs and protein-coding transcripts. 33,045 LncRNAs and 30,215 coding transcripts can be detected by the second-generation LncRNA microarray. According to microarray data, a total of 4364 significantly dysregulated lncRNAs (Fold Change ≥2.0, *P\<*0.05) including 2365 up-regulated and 1999 down-regulated lncRNAs were found to be differentially expressed between the PDAC and corresponding adjacent normal tissues (Fig [1](#F1){ref-type="fig"}). In addition, 3857 up-regulated mRNAs and 1005 down-regulated mRNAs were determined between them (Fold Change ≥2.0, *P*\<0.05).

GO and KEGG pathway analyses
----------------------------

The up- and down-regulated mRNAs were analyzed in GO analysis ([www.geneontology.org](http://www.geneontology.org)). Gene and gene product enrichment including biological processes, cellular components and molecular functions were determined in GO analysis. In the GO analysis, the highest enriched GO targeted by up-regulated transcripts was macromolecular localization (biological process \[BP\]), cytoplasm (cellular component \[CC\]) and protein binding (molecular function \[MF\]). Meanwhile, release of cytochrome c from mitochondria (BP), stereocilium (CC) and rector activity (MF) were the highest enriched GOs targeted by down-regulated transcripts (Fig [2](#F2){ref-type="fig"}).

KEGG pathway analysis identified 42 and 8 gene pathways by up- and down regulated mRNAs, and the top 10 pathways related to up- and 8 pathways related to down-regulated mRNAs are shown in Fig [3](#F3){ref-type="fig"}. In KEGG analysis of the up-regulated transcripts, the most enriched network was "Phagosome-Homo sapiens (human)" (Fisher *P* value= 9.10703E-06). What is more, the pathway analysis was also proven to be related to PDAC-associated biological behaviors, such as pathways in cancer, TGF-beta signaling pathway and cell cycle (Fig [3](#F3){ref-type="fig"}A). As for pathway analysis of the down-regulated transcripts, the top pathways were Mineral absorption, Arachidonic acid metabolism and PPAR signaling pathway (Fig [3](#F3){ref-type="fig"}B).

RT-PCR validation
-----------------

For further study, we selected 7 significantly differentially expressed lncRNAs (CTD-2244C20.1, RP11-263F15.1, LOC541471, STK16, AF293366, BC031940 and BC047917) to conduct RT-PCR for validating the expression levels of lncRNAs in 5 PDAC tissues and the corresponding adjacent tissues. As a result, CTD-2244C20.1, RP11-263F15.1 and LOC541471 were found to be significantly over-expressed in the cancer tissues, while the other lncRNAs did not undergo significant changes (Fig [4](#F4){ref-type="fig"}).

Clinicopathological features and diagnostic significance of lncRNA RP11-263F15.1
--------------------------------------------------------------------------------

Knowing that lncRNA RP11-263F15.1 was over-expressed significantly in PDAC tissues compared with that in adjacent non-cancerous tissues (*P\<*0.001), we then summarized the relationship between lncRNA RP11-263F15.1 expression and the clinicopathological characteristics of the other 66 PDAC patients by categorizing lncRNA RP11-263F15.1 expression as high or low *versus* the adjacent non-cancerous tissues. As shown in Table [2](#T2){ref-type="table"}, lncRNA RP11-263F15.1 was association with histologic differentiation of PDAC cells (Table [2](#T2){ref-type="table"}). No significant correlation was observed between RP11-263F15.1 expression level and age, gender, tumor diameter and location, lymph node metastasis, distant metastasis and perineural invasion. To determine whether RP11-263F15.1 could be identified as a novel biomarker to distinguish PDAC from non-cancerous tissues, receiver operating characteristic (ROC) curve was constructed by grouping all cancer and normal tissue specimens into a class. The expression level of RP11-263F15.1 was obtained from RT-PCR of a cohort of the 66 PDAC patients. The area under the curve (AUC) was 0.843 (95% confidence intervals \[CI\] =0.774-0.911, *P\<*0.001) (Fig [5](#F5){ref-type="fig"}), indicating that RP11-263F15.1 may be a potential diagnostic biomarker of PDAC.

Prognostic value of RP11-263F15.1 in PDAC patients
--------------------------------------------------

A follow-up study was conducted to assess the prognostic value of RP11-263F15.1. As shown in Fig [6](#F6){ref-type="fig"}, the KM analysis revealed that high expression of RP11-263F15.1 was associated with a shorter overall survival (OS) (median OS:12.0 months) as compared the low-expression group (median OS:25.1 months) (*P\<*0.001). Besides, univariate Cox regression of OS revealed that high expression of RP11-263F15.1 (*P*=0.001) and poor histologic differentiation (P=0.021) were prognostic factors. However, the multivariate analysis suggested that RP11-263F15.1 expression and poor histologic differentiation were not independent prognostic indicators in patients with PDAC (Table [3](#T3){ref-type="table"}).

Discussion
==========

Pancreatic ductal adenocarcinoma is the commonest form of pancreatic cancer with a low survival rate due to its highly malignant behavior [@B18], [@B19]. Our current understanding about the pathogenesis of PDAC mainly depends on numerous protein-coding genes, knowing that some protein-coding genes play important roles in the initiation and progression of PDAC. It was reported [@B20] that KRAS mutation was detectable in 95% human PDAC cases, and the acquisition of mutant KRAS was an initial event in PDAC. Mutant KRAS gene was found to be a driver of PDAC development through promoting cell proliferation, differentiation and invasion [@B21], [@B22]. Nevertheless, the molecular mechanism underlying PDAC has not been clarified clearly, making PDAC a clinically challenging disease [@B23]. In recent years, emerging evidence has demonstrated that lncRNAs play important roles in multiple functions in PDAC, including cell growth, survival, invasion, metastasis, angiogenesis and apoptosis [@B24]. Identification of lncRNA involvement in the carcinogenesis of PDAC may provide new strategies for the diagnosis and treatment of PDAC.

In the present study, we conducted a microarray to explore the expression of lncRNA and mRNA in the PDAC tissues*versus* the corresponding adjacent non-cancerous tissues, and found 2365 up-regulated and 1999 down-regulated lncRNAs in PDAC tissues *versus* adjacent non-cancerous tissues. Meanwhile, 3857 up-regulated mRNAs and 1005 down-regulated mRNAs were detected in PDAC tissues versus adjacent non-cancerous tissues. Our microarray analysis suggested that lncRNAs may play functional roles in the process of PDAC tumorigenesis. Previous studies investigated the lncRNA expression profile of pancreatic cancer tissues by microarray. Fu *et al.* [@B25] analyzed PDAC microarray datasets and identified 34 differentially expressed lncRNAs in PDAC. In addition, they found that AFAP1-AS1, UCA1 and ENSG00000218510 were involved in PDAC carcinogenesis. Zhou and colleagues [@B26] investigated the lncRNA expression pattern in 3 pairs of PDAC *versus* adjacent non-cancerous tissues and found 2331 up-regulated and 1641 down-regulated lncRNAs in PDAC*versus* adjacent non-cancerous tissues. Consequently, the expression of HOTAIRM1 was confirmed in a small cohort of 12 PDAC patients by qRT-PCR. The lncRNA microarray provides a practical method to discover novel lncRNAs involved in PDAC tumorigenesis. The microarray studies on PDAC-related lncRNAs are summarized in Table [4](#T4){ref-type="table"}.

Further GO and pathway analyses were utilized to study the biological functions of lncRNAs and relative mRNAs. The result of GO analysis showed that the up-regulated gene profile was closely correlated with the protein function such as protein localization, proteasome accessory complex and macromolecule localization. The down-regulated gene profile includes Golgi to plasma membrane transport, release of cytochrome C from mitochondria, plasma membrane and receptor periphery. This result supports the notion that although lncRNAs do not code protein sequence, they can regulate protein metabolism and functions to affect the biological process. Meanwhile, pathway analysis showed that the main up-regulated gene profile was associated with carcinogenesis such as phagosome, focal adhesion, pathways in cancer, transforming growth factor-beta (TGF-beta) signaling pathway and cell cycle. The result is consistent with previous studies in human PDAC tissues, reporting that the up-regulated genes in PDAC were associated with pathways in cancer [@B27]. Another study reported that TGF-beta receptor 1 and epidermal growth factor (EGF) played important roles in the pathogenesis of pancreatic cancer [@B28]. Surprisingly, pathway analysis showed that the main down-regulated gene profile was correlated with nutrition metabolism including mineral absorption, arachidonic acid metabolism, PPAR signaling pathway, endocrine and other factor-regulated calcium reabsorptions. This result suggests that metabolism is somehow changed during the procession of tumorigenesis in PDAC, supporting the notion that interplay between evolving PDAC and whole body metabolism contributes to disease pathogenesis [@B29].

To validate the expression of selected lncRNAs in PDAC, we conducted a qRT-PCR and the result showed that CTD-2244C20.1, RP11-263F15.1 and LOC541471 were significantly over-expressed in PDAC tissues compared with adjacent non-cancerous tissues, while STK16, AF293366, BC031940 and BC047917 were not differentially expressed between them. Among these lncRNAs, the expression level of RP11-263F15.1 was the most striking change between PDAC tissue and non-cancerous tissue, so RP11-263F15.1 was chosen to the further study. In the present study, we recruited a large cohort of 66 patients with PDAC to validate the expression of RP11-263F15.1. It was found that RP11-263F15.1 was significantly elevated in PDAC tissues to a greater extent than in adjacent tissues. Besides, a high expression level of RP11-263F15.1 was associated with poor histologic differentiation. The area under the ROC curve was 0.843 (P\<0.001), suggesting that RP11-263F15.1 may play an important role in PDAC progression and could be a potential diagnostic biomarker for PDAC. In addition, our study showed that high expression of RP11-263F15.1 was associated with a shorter OS in PDAC patients, although it is not an independent indictor for predicting the prognosis of PDAC. Compared to mRNA, lncRNA has tissue-specific expression pattern which may provide new biomarker for clinical utility to distinguish the patient from heath individual. The expression level of RP11-263F15.1 increased in PDAC compared to non-cancerous tissue and high expression level of RP11-263F15.1 was associated with a shorter OS in PDAC patient, suggesting that RP11-263F15.1 may be an important factor in the progression of PDAC.

Previously, Ye *et al.* [@B30] predicted the regulation mechanism of pancreatic cancer by bioinformatics and found that 21 lncRNAs related to lncRNA-miRNA-mRNA pathway were differentially expressed in pancreatic cancer, suggesting that lncRNA dysfunction is a critical step in the progression in PDAC. Similar to our study, Müller and colleagues [@B31] found that 43 lncRNAs were differentially expressed in six pancreatic cancer tissues and five control tissues by next-generation sequencing. Wang *et al.* [@B32] found that lncRNA HOTTIP-005, XLOC_006390 and RP-567G11.1 were increased as shown by microarray, and they may prove to be diagnostic biomarkers for pancreatic cancer. Several other lncRNAs (lncRNA-ATB, LOC389641 and PVT1) have been proved to have diagnostic and prognostic values in PDAC [@B33]-[@B35]. All these studies and ours suggest that lncRNAs have potential diagnostic and prognostic values in PDAC. However, few lncRNAs have been functionally characterized, although thousands of lncRNAs are aberrantly expressed as shown by sequencing or microarray methods. Further study is needed to investigate the mechanism underlying the carcinogenesis of PDAC.

In summary, our study demonstrated that 4364 lncRNAs and 4862 related mRNAs were significantly dysregulated in PDAC tissues versus adjacent non-cancerous tissues. GO and pathway analyses showed that up-regulated lncRNAs that related to several pathways, especially TGF-beta signaling pathway, were associated with carcinogenesis, and phagosome and cell cycle were closely correlated with PDAC progression. Interestingly, almost all down-regulated lncRNAs were associated with metabolism, such as mineral absorption, arachidonic acid metabolism, PPAR signaling pathway, endocrine and other factor-regulated calcium reabsorption. In addition, we found that RP11-263F15.1 was significantly over-expressed in PDAC tissues, and that RP11-263F15.1 was associated with histologic differentiation. KM analysis showed that a higher expression of RP11-263F15.1 was associated with a shorter OS. However, RP11-263F15.1 was not an independent indictor of prognosis for patients with PDAC. Cumulatively, these findings indicate that RP11-263F15.1 plays an important role in the initiation and progression of PDAC and may prove to be a potential diagnostic or prognostic biomarker for PDAC.
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###### 

**Differentially expressed lncRNAs and mRNAs in pancreatic adenocarcinoma (PDAC) and adjacent normal tissues.**Hierarchical cluster analysis of PDAC and adjacent normal tissues was performed to assess the significant expression of lncRNAs (A) and mRNAs (B). The Box Plot shows the distributions of the intensities from the cancerous and adjacent tissues in lncRNAs (C) and mRNAs (D). After normalization, the distributions of log2-ratios among all specimens were nearly the same. The Scatter-Plot shows differences in the expression of lncRNAs (E) and mRNAs (F) between the PDAC and adjacent normal tissues. The green lines are fold-change lines (The default fold-change value given is 2.0). The lncRNAs and mRNAs above the top green line and below the bottom green line indicate more than 2.0 fold change of lncRNAs and mRNAs between the PDAC and adjacent normal tissues. The volcano plot illustrates the distribution of the data in the lncRNA profile (G). The green line in the volcano plot shows the significant fold-hange in lncRNAs.
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###### 

**Gene Ontology (GO) analysis of mRNAs.**A1-A3: The highest enriched GO targeted by up-regulated transcripts in the biological process (BP) (A1), cellular component (CC) (A2) and molecular function (MF) (A3). B1-B3: The highest enriched GO targeted by up-regulated transcripts in the BP (B1), CC (B2) and MF (B3).
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###### 

**The results of KEGG pathway analysis.**The top 10 pathways of up-regulated mRNAs (A) and all the pathways of down-regulated mRNAs (B) are listed, showing the leading pathways associated with the up-regulated (C) and down-regulated (D) mRNAs.
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![**Verification of the expression levels of selected lncRNAs between the PDAC and adjacent normal tissues by RT-PCR.**A-G shows the expression levels of CTD-2244C20.1, RP11-263F15.1, LOC541471, STK16, AF293366, BC031940 and BC04791, respectively.](jcav08p2740g008){#F4}

![**Assessment of the diagnostic value of RP11-263F15.1 by receiver operating characteristic (ROC) curve.** AUC was 0.843 and 95% CI was 0.774-0.911.](jcav08p2740g009){#F5}

![The Kaplan-Meier analysis of patients with PDAC between higher (median: 12.0 months) and lower (median: 25.1 months) RP11-263F15.1 groups (*P\<*0.001).](jcav08p2740g010){#F6}

###### 

Primers used for cDNA synthesis and real-time PCR of lncRNAs

  NAME                          Prime Sequence                  Length
  ----------------------------- ------------------------------- --------
  U6                            F: 5\' CTCGCTTCGGCAGCACA        94bp
  R: 5\' AACGCTTCACGAATTTGCGT                                   
  CTD-2244C20.1                 F: 5\' TCACTCACAGGATGCAGAAG     100bp
  R: 5\' CCAATCCATTCCGAGTACTT                                   
  RP11-263F15.1                 F: 5\' GGATGCTGAAGCCTGGTT       150bp
  R: 5\' TTCATGCTCAGCCGTGACT                                    
  LOC541471                     F: 5\' TGGGAGATGAAACAGGAAGCT    120bp
  R: 5\' CTGCATTCCGGCTGTGATC                                    
  STK16                         F: 5\' CGTTCAAGCTCATACATGGT     120bp
  R: 5\' GGTTTGAAGCCCAGCTAAG                                    
  AF293366                      F: 5\' AGTCAATGATAAACTCACAAGT   129bp
  R: 5\' TCCTTCATTCTTTGACCGTG                                   
  BC031940                      F: 5\' TCAGCGGAGGCACATTTCTA     130bp
  R: 5\' CCAACTCTTGCCAACCATCA                                   
  BC047917                      F: 5\' CGGTTGGGTCTGTTCTTG       112bp
  R: 5\' AGGGTGGGTCTATGTCTG                                     

###### 

The clinical characteristics of patients with pancreatic ductal adenocarcinoma

  ----------------------------------------------------------------------------------------------------------
  Characteristics              Cases (N)   Lnc RP11-263F15.1 expression   P-value                
  ---------------------------- ----------- ------------------------------ --------- ---- ------- -----------
  Age                                                                                            

  \<65                         34          5                              7.58      29   43.94   0.660

  ≥65                          32          6                              9.09      26   39.39   

  Gender                                                                                         

  Male                         33          6                              9.09      27   40.91   0.740

  Female                       33          5                              7.58      28   42.42   

  Diameter                                                                                       

  \<3cm                        15          1                              1.64      14   22.95   0.726

  ≥3cm                         46          7                              11.48     39   63.93   

  Location                                                                                       

  head                         35          5                              8.06      30   48.39   0.226

  Body and tail                27          6                              9.68      21   33.87   

  Histologic differentiation                                                                     

  Well and moderately          38          2                              3.39      36   61.02   0.001^\*^

  Poorly                       21          9                              15.25     12   20.34   

  pT stage                                                                                       

  T~1~andT~2~                  6           1                              1.96      5    9.80    0.548

  T~3~ andT~4~                 45          5                              9.80      40   78.43   

  Lymph node\                                                                                    
  metastasis                                                                                     

  Present                      33          5                              9.80      28   54.90   0.093

  Absent                       18          1                              1.96      17   33.33   

  Metastasis                                                                                     

  Present                      12          5                              8.93      7    12.50   0.079

  Absent                       44          6                              10.71     38   67.86   

  Perineural invasion                                                                            

  Yes                          48          7                              12.28     41   71.93   0.379

  No                           9           3                              5.26      6    10.53   
  ----------------------------------------------------------------------------------------------------------

\*Statistically significant (p\<0.05)

###### 

Univariate and multivariate survival analysis in patients with PDAC.

  Characteristics                                Univariate analysis   Multivariate analysis                                       
  ---------------------------------------------- --------------------- ----------------------- ----------- ------- --------------- -------
  Age (≥65 vs.\<65)                              0.499                 0.132-1.892             0.286       0.775   0.108-5.545     0.800
  Gender (Male vs. Female)                       0.497                 0.144-1.716             0.258       0.244   0.018-3.237     0.285
  Diameter (≥3cm vs.\<3cm)                       0.551                 0.160-1.898             0.345       1.906   0.242-14.984    0.540
  Location (head vs. distal)                     0.524                 0.138-1.986             0.342       0.378   0.052-2.745     0.336
  Histologic differentiation (well vs. poorly)   0.232                 0.067-0.805             0.021^\*^   1.718   0.022-131.629   0.807
  Lymph node metastasis (Yes vs. No)             0.297                 0.077-1.146             0.060       0.043   0.001-2.238     0.119
  Metastasis (Yes vs. No)                        2.261                 0.583-8.766             0.238       4.259   0.217-83.579    0.340
  Perineural invasion (Yes vs. No)               0.470                 0.123-1.804             0.271       1.904   0.061-59.226    0.713
  RP11-263F15.1 expression (high vs. low)        7.580                 2.169-26.494            0.001^\*^   2.646   0.772-710.534   0.076

\* Statistically significant (p\<0.05)

###### 

Summary of microarray studies on lncRNA related to PDAC.

  Author            Country   Publish year   Data source                                               Sample size in microarray                                                                                                              Differently expressed lncRNAs and mRNAs                     Candidate lncRNAs and related mRNA     Utility
  ----------------- --------- -------------- --------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- -------------------------------------- -----------------------------------------------------------
  Tahira *et al.*   Brasil    2011           Sptted custom-cDNA microarray                             9 non-pancreatic tissue, 15 primary pancreatic adenocarcinoma, 6 metastases from primary panceatic tumors and 8 chronic pancreatitis   1267 protein-coding mRNAs and 340 putative noncoding RNAs   PPP3CB, MAP3K14 and DAPK1              Correlate in PDAC or metastasis
  Li *et al.*       China     2014           LncRNA expression microarray                              3 pairs of PDAC patients                                                                                                               3220 upregulated and 945 downregulated lncRNAs              lncRNA BC008363                        Independent prognostic factor
  Ye *et al.*       China     2014           GSE30134 expression profiles                              18 pancreatic cancers and 9 normal pancreas                                                                                            21 lncRNAs                                                  \-                                     \-
  Li *et al.*       China     2015           Arraystar human lncRNA microarrays, V2                    12 samples                                                                                                                             27 upregulated lncRNAs                                      HOTTIP                                 Promote cell proliferation, invasion, and chemoresistance
  Wang *et al.*     China     2015           Agilent Array platform                                    PanIN cell line and PDAC cell line                                                                                                     319 upregulated lncRNAs and 571 downregulated lncRNAs       8 lncRNAs and 5 protein-coding genes   Wnt Pathway-Associated
  Wang *et al.*     China     2015           Arraystar Human LncRNA Microarray, V3                     12 samples                                                                                                                             36 upregulated and 78 downregulated lncRNAs                 HOTTIP-005 and RP11-567G11.1           prognostic and Diagnostic biomarker
  Ye *et al*.       China     2015           Arraystar Human LncRNA Microarray, V3                     12 samples                                                                                                                             3534 upregulated lncRNAs and 4751 downregulated lncRNAs     AFAP1-AS1                              Poor survival and short-term recurrence
  fu *et al.*       China     2016           Affymetrix GeneChip Human Genome HG-U133 Plus 2.0 array   84 samples                                                                                                                             20 upregulated and 15 downregulated lncRNAs                 AFAP1-AS1, UCA1 and ENSG00000218510    Diagnostic biomarker
  hu *et al.*       China     2016           LncRNA Human Gene Expression Microarray V4.0              PANC-1 cells treated with or without fenofibrate                                                                                       549 upregulated lncRNAs and 852 down regulated lncRNAs      LncRNA MEG3                            Promote pancreatic cancer cells proliferation
  Li *et al.*       China     2016           Agilent Gene Expression Analysis                          6 samples                                                                                                                              \-                                                          lncRNA-NUTF2P3-001                     Derepress the miR-3923/KRAS pathway
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